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induced apoptosis for example of endothelial cells or bone mar-
row stem cells is clinically relevant as initiating step for normal
tissue damage after radiotherapy.
We have established several gene-therapeutic approaches to
suppress radiation induced apoptosis by overexpression of
super-oxide dismutase (SOD) and P-glycoprotein (P-gp) the prod-
uct of the multi-drug resistance gene (MDR). Clonogenic assays
showed that radioresistance can be induced in normal tissue
cells (e.g. human primary lung fibroblasts), whereas the survival
of human tumor cells (e.g. HeLa) after radiotherapy is not
altered. Using differential gene expression analysis and quanti-
tative real-time PCR, we showed up-regulation of detoxification
genes and down-regulation of pro-apoptotic genes (e.g. CASP1,
CASP4).
Targeting the apoptotic pathway to induce radioresistance in
normal tissue cells is a potential strategy to increase the thera-
peutic index in radiation oncology.
doi:10.1016/j.ejcsup.2006.04.042
S42. CHALLENGES IN DEFINING GENETIC RISKS FOR FAMILIAL
COLORECTAL CANCER
Peter Propping. Institute of Human Genetics, University of Bonn,
Bonn, Germany.
Twenty to twenty-five percent of all cases of colorectal cancer
(CRC) show some familiarity. Although the role of genes is not
yet completely understood, a number of well-defined genetic dis-
ease entities is known to contribute to the familiarity: Lynch syn-
drome (formerly hereditary nonpolyposis colorectal cancer,
HNPCC), familial adenomatous polyposis (FAP), MYH-associated
polyposis (MAP), juvenile polyposis, Peutz–Jeghers syndrome.
The most common genetic form of CRC is Lynch syndrome that
is responsible for 2–3% of all cases. The analysis of these diseases
led to valuable insights into the disease process also of the spo-
radic forms of CRC.
We need a filter system within the public health care system
that allows the detection of families with an increased genetic
risk. Individuals belonging to such families should first undergo
genetic counselling. Genetic analysis can largely differentiate
between the risks. Persons at increased risk should be included
in a risk-adapted screening programme. Only specialized centers
for inherited CRC will be able to efficiently organize programs of
CRC prevention.
The ongoing collaborative study of the German Cancer Aid will
give clear data as to the efficacy of systematic cancer prevention
in Lynch syndrome through early detection, particularly through
colonoscopy and gynecological examinations.
doi:10.1016/j.ejcsup.2006.04.043
S43. MOLECULAR DIAGNOSIS OF HEREDITARY COLORECTAL
CANCERS
Hans K. Schackert. Department of Surgical Research, Technische
Universita¨t Dresden, Germany.
Hereditary colorectal cancer accounts for up to 5% of all colo-
rectal cancers. A variety of known and unknown genes are
responsible for the two known phenotypes. Familial adenoma-
tous polyposis coli (FAP) is phenotypically characterized by
hundreds or even thousands of polyps in the colon and rectum
and by a very high incidence of colorectal cancer at young age.
FAP is caused by the tumour suppressor gene APC and is a
highly penetrant autosomal condition, while the phenotypically
similar MUTYH-associated polyposis is an autosomal recessive
disease.
The much more frequent hereditary non-polyposis colorectal
cancer syndrome (HNPCC) is caused by mutations in five mis-
match repair (MMR) genes. Although no clear-cut genotype/phe-
notype correlations in pathogenic mutations carriers of the
same MMR gene have been identified, distinct phenotypic differ-
ences are associated with mutations in different MMR genes. The
mode of inheritance of HNPCC is autosomal dominant, yet a
small but increasing number of very young patients have been
reported as carriers of biallelic MMR gene mutations. Notably,
their phenotype is different from the HNPCC phenotype and
resembles the phenotype of MMR gene knockout mice. In addi-
tion to an incomplete penetrance of about 80% for colorectal can-
cers, and susceptibility to a wide range of tumours, the age of
onset of HNPCC varies widely, ranging from 16 to 90 years. We
have identified additional genetic factors located in p53 and RNA-
SEL that influence age of disease onset in HNPCC patients carry-
ing a pathogenic MMR germline mutation.
In conclusion, mutations in a variety of genes can cause
hereditary colorectal cancer. In addition to genetic heterogeneity,
there is evidence for multiple genetic factors that contribute to
the development of disease. Identification of causative genetic
and environmental factors may contribute to a more detailed
tumour risk assessment in carriers of mutations in MMR genes.
Particularly, the knowledge of the age of onset of disease in carri-
ers of pathogenic germline mutations in MMR genes might affect
preventive strategies, including age at first surveillance, surveil-
lance intervals, and age at preventive surgery.
doi:10.1016/j.ejcsup.2006.04.044
S44. EGFR-SIGNALLING IN COLON CANCER
R. Kopp. Department of Surgery, Klinikum Grosshadern, LMU Munich,
Germany.
Activation of the epidermal growth factor receptor (EGFR) path-
way seems to be involved in the regulation of proliferation and
invasion in gastrointestinal tumors. In colon cancer increased
EGFR levels were reported in advanced and more invasive carci-
nomas. Recently EGFR-inhibitors are used as a new treatment
option in patients not responding to standard chemotherapy.
However, EGFR-signalling is dependent on the presence of var-
ious EGFR ligands and mechanisms of ligand presentation. In
addition several other mechanisms involved in the regulation
of EGFR binding have been reported (PKC, Syk, Mig6, SIRPs).
Furthermore costimulatory effects between other G-protein
coupled receptor (GPCR) were shown to increase tumor cell
proliferation.
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Therefore, EGFR signalling in colon cancer is modulated at the
level of receptor capacity, receptor heterodimerization, regulation
of intracellular tyrosine kinase activity, ligand presentation and
by other costimulatory receptor pathways. These mechanisms
have to be considered when therapeutic strategies using EGFR-
inhibition are evaluated.
doi:10.1016/j.ejcsup.2006.04.045
S45. THERAPEUTIC DECISIONS FROM MOLECULAR STAGING IN
COLORECTAL CANCER
Ju¨rgen Weitz. Department of Surgery, University of Heidelberg,
Germany.
Colorectal cancer is one of the most prevalent cancers world-
wide. Whereas surgery is the basis of therapy, chemo- and/or
radiotherapy are used frequently to reduce local and distant
recurrences. Many prognostic factors have been defined, with
only the UICC classification being relevant for therapeutic deci-
sions at present. The prognosis for an individual patient, how-
ever, still cannot be sufficiently predicted. Therefore, many
patients will receive radio-/chemotherapy that do not benefit
from this treatment. Other patients might not receive radio-/che-
motherapy as they are judged to be at a low risk for recurrence,
but will develop recurrent disease. Better prognostic factors are
therefore needed, in order to individualize the therapeutic strat-
egy. As recurrences after complete tumor removal are most likely
caused by disseminated tumor cells, it seems to be a logical
approach to develop methods to detect these cells. Ideally,
patients in whom tumor cells can be detected should have a
worse prognosis and should therefore benefit from adjuvant
therapeutic strategies. The effect of this therapy should then
become apparent by a reduced detection rate of disseminated
tumor cells. Even though some studies demonstrate a prognostic
relevance of disseminated tumor cells, the prognostic relevance
of these cells is not generally accepted. Due to the heterogeneity
of disseminated tumor cells, demonstration of the mere pres-
ence of these cells will most likely not be an adequate basis
for therapeutic decisions. Molecular characterization of dissemi-
nated tumor cells and/or of the primary tumor might be a more
successful approach in this respect. The clinical relevance of
molecular staging for therapeutic decisions, however, has still
to be proven in well designed clinical trials.
doi:10.1016/j.ejcsup.2006.04.046
S46. ANTI-TUMOUR POTENTIAL OF ZOLEDRONIC ACID
(Zometa)
Jonathan Green. Novartis Institutes for BioMedical Research, Basel,
Switzerland.
Bisphosphonates have been used extensively for more than 3 dec-
ades to inhibit osteoclastic activity in a variety of benign and
malignant diseases characterized by increased bone resorption.
Due to the bisphosphonate moiety, these compounds bind avidly
to bone mineral and accumulate at sites of active bone turnover.
During bone resorption they are released and ingested by osteo-
clasts via fluid-phase endocytosis. The nitrogen-containing bis-
phosphonates (N-BPs) inhibit a key intracellular enzyme in the
mevalonate pathway, farnesyl pyrophosphate synthase, thereby
reducing prenylation of small GTPase signalling proteins that
are essential for osteoclast function and survival. Consequently,
bone resorption is impaired and osteoclast apoptosis is induced.
Zoledronic acid (Zometa) is a novel compound which retains
the bisphosphonate ‘‘bone hook’’ and possesses a heterocyclic
imidazole substituent containing 2 nitrogen atoms. X-ray crystal-
lography studies with human farnesyl pyrophosphate synthase
have shown that the zoledronic acid molecule binds with high
affinity to the active site of the enzyme and induces an irrevers-
ible conformational change that prevents further access of sub-
strate. Structure-activity studies with more than 300 novel
compounds identified zoledronic acid as the lead candidate for
clinical development due to its outstanding potency as an inhib-
itor of osteoclastic bone resorption both in vitro and in vivo, and
its excellent in vivo tolerability.
In animal models of breast cancer, prostate cancer, osteosar-
coma and haematological malignancies such as multiple mye-
loma and leukaemia, low doses of zoledronic acid markedly
inhibit osteoclastic activity and thus reduce tumour-induced oste-
olysis and hypercalcaemia. Bone is a rich source of growth factors
which are released during bone resorption and can stimulate
tumour cell proliferation. By inhibiting osteoclastic activity, zoled-
ronic acid reduces the release of tumour growth factors from bone
and thus interrupts this stimulatory cycle. Furthermore, the high
local concentration of bisphosphonate at an osteolytic site may
exert direct cytostatic and apoptotic effects on the tumour cells
in a bone metastasis. Extensive in vitro data show that zoledronic
acid is cytostatic and pro-apoptotic against a variety of human
tumour cell lines. Interestingly, zoledronic acid enhances the effi-
cacy of some cytotoxic drugs in a synergistic manner, especially
when the drugs are administered sequentially rather than con-
comitantly. Apart from these direct effects on tumour cell prolifer-
ation and viability, N-BPs also impair the metastatic behaviour of
tumour cells and modulate the host’s response to neoplastic dis-
ease. In vitro, zoledronic acid potently inhibits tumour cell inva-
sion through extracellular matrix, decreases cell adhesion to
both mineralized and non-mineralized matrices, and disrupts soft
tissue angiogenesis. Preclinical data from a variety of animal
tumour models demonstrate that, in vivo, these effects translate
into reduced tumour load, increased tumour cell apoptosis, and
in some cases delayed disease progression with a corresponding
survival benefit. Although these effects have been predominantly
observed in models of bone metastases in nude mice, emerging
data indicate that zoledronic acid can also inhibit the growth of
primary soft tissue tumours in transgenic animals by a mecha-
nism that apparently involves inhibition of angiogenesis and dis-
rupted macrophage function.
Recently, another intriguing facet has been added to the phar-
macological profile of the N-BPs. It has been known for many
years that these compounds interact with the immune system
to produce an acute phase response in a significant proportion
of patients, especially when administered intravenously, but the
molecular mechanism remained elusive. It is now known that
this effect is caused by inhibition of farnesyl pyrophosphate syn-
thase in monocytes, leading to accumulation of upstream metab-
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